Kite Pharma (KITE) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Kite Pharma (KITE) Tops Q4 EPS by 1c
March 26, 2015 8:01 AM EDT
SANTA MONICA, Calif., March 26, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today reported full-year and fourth quarter 2014 financial results for the period ended December 31, 2014.
"2014 was a transformative year for Kite, marked by achieving several key corporate and clinical milestones," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer. "In addition to our successful IPO and follow-on offering, we expanded our management team with world-class talent, filed our first... More
March 25, 2015 9:00 PM EDT
SANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on chimeric antigen receptor (CAR) and T cell receptor (TCR) gene therapy for the treatment of... More
March 25, 2015 9:00 PM EDT
SANTA MONICA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on chimeric antigen receptor (CAR) and T cell receptor (TCR) gene therapy for the treatment of... More
